Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Jul 30 · below the Ichimoku cloud · RSI 31 · MACD below its signal
None of the 29 investors followed here reported a position in ADVB in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ADVB trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for ADVB.
No analyst coverage for this instrument.
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. It offers A+Pre, a device that prepares blood samples for testing; the AC-1000, a device that separates cancer cells from the rest of the blood; A+SCDrop, a device that isolates individual cells; and A+CellScan, a device that stains and automatically counts cancer cells. The company provides developed dye kits used to identify different types of cancer cells. It also offers FinTruth financial verification agent platform, an enterprise AI financial verification platform designed to compare and verify financial analysis and AI-generated financial content against underlying source documents and financial rules, and to produce source-traceable and auditable results. The company was founded in 2014 and is based in Tsuen Wan, Hong Kong.